MI-CP151 was a period 1b randomised, double-blind, placebo managed, dose-escalation, multicentre study to evaluate several intravenous doses of sifalimumab, in adult people with dermatomyositis or polymyositis (NCT00533091). Main trial objectives ended up To judge the protection and tolerability of sifalimumab in dermatomyositis or polymyositis clients, though one of several exploratory https://normani554ugr7.wikicommunications.com/user